Stevanato Group S P A (STVN) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Stevanato Group S p a   (NYSE: STVN)

Stevanato Group S P A 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Stevanato Group S P A in the fourth quarter 2025?
Stevanato Group S p a achieved a return on average equity (ROE) of 9.41 % in its fourth quarter 2025, which is below Stevanato Group S P A 's average return on equity, which stands at 11.25%.

ROE has advanced compared to 8.03% in the third quarter 2025, due to net income growth.

Within the Medical Equipment & Supplies industry 47 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 1724.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change 5.85 % 5.85 % 5.85 % 5.85 % -
Y / Y Net Income Change 18.74 % - - - -19.17 %
Net Income (TTM) in Millions 157 132 132 132 132
Return On Equity (TTM) 9.41 % 8.03 % 8.15 % 8.26 % 8.39 %
STVN's Total Ranking # 1724 # 0 # # #
Equity (TTM) in Millions 1,665 1,665 1,665 1,665 1,573
Seq. Equity Change 0 % 0 % 0 % 5.85 % 0 %
Seq. Net Income Change - - - - -

Back to STVN Management Effectiveness >> STVN's 5 Years Annual ROE >> Compare STVN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 48
Sector # 171
Overall # 1724

Return On Equity Statistics
High Average Low
14.36 %
11.25 %
8.39 %
(Dec 31 2022)   (Dec 31 2024)





STVN Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2019)
2021
Total Equity in Millions 1,665 1,573 1,269 1,115 379
Y / Y Equity Change 5.85 % 23.99 % 13.73 % 194.07 % -
Net Income in Millions 157 132 163 160 43
Y / Y Net Income Change 18.74 % -19.17 % 1.87 % 269.67 % -
Return On Equity 9.41 % 8.39 % 12.86 % 14.36 % 11.42 %

Back to STVN Management Effectiveness >> STVN's 5 Years Annual ROE >> Compare STVN ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 9.41 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
STVN's' Return on Equity at Yahoo Finance
STVN's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for STVN's Competitors
Subscribers only: Roe for Stevanato Group S P A 's Suppliers
Subscribers only: Return On Equity for STVN's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Resmed Inc   25.18 %
Encompass Health Corporation  24.76 %
Prestige Consumer Healthcare Inc   24.66 %
Catalyst Pharmaceuticals Inc   24.32 %
Collegium Pharmaceutical Inc   24.11 %
Xoma Royalty Corporation  23.97 %
Chemed Corporation  23.92 %
Iradimed Corporation  23.83 %
Lifevantage Corp  23.04 %
Hims and Hers Health Inc   22.99 %
Vertex Pharmaceuticals Inc  22.70 %
Pacs Group Inc   22.54 %
Spero Therapeutics Inc   22.53 %
Iqvia Holdings Inc   22.05 %
Ge Healthcare Technologies Inc   21.90 %
Msa Safety Inc  21.82 %
Mimedx Group Inc   21.24 %
Universal Health Services Inc   21.19 %
Inspire Medical Systems inc   21.07 %
Astrazeneca Plc  21.00 %
Haemonetics Corporation  20.80 %
Sbc Medical Group Holdings Incorporated  20.79 %
Lantheus Holdings Inc   20.58 %
Electromed Inc   20.54 %
Teva Pharmaceutical Industries Limited  20.07 %
Harmony Biosciences Holdings inc   19.84 %
Pediatrix Medical Group Inc   19.58 %
United Therapeutics Corporation  19.30 %
Krystal Biotech Inc   18.69 %
Argenx Se  17.64 %

Date modified: 2026-07-07T13:27:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.